FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W88459169> ?p ?o ?g. }

• W88459169 endingPage "24" @default.
• W88459169 startingPage "413" @default.
• W88459169 abstract "The prevalence and the clinical gravity of the various histopathological varieties of renal osteodystrophy in dialysis patients depends on the severity of both the aluminium intoxication and that of hyperparathyroidism. The prevalence of bone pains, fractures and hypercalcemias are the highest in adynamic bone diseases (ABD) with severe aluminium intoxication, then in osteitis fibrosa and mixed osteopathy, in the ABD with moderate aluminium intoxication and rare in the mild lesion in spite of similar moderate aluminium intoxication. In the absence of aluminium intoxication, hypercalcemia and hyperphosphatemia prevalence is higher only when intact PTH is more that 4 times the upper limit of normal. When PTH is between 1 and 2 folds the ULN this prevalence is null and bone mineral density is the highest. 2. The low turnover aluminic bone diseases (osteomalacic or adynamic) will be cured by long term deferoxamine treatment. The hazards of such treatment justify the performance of a bone biopsy to ensure the diagnosis. Their prevention relies on adequate treatment of tapwater and definitive exclusion of long term administration of aluminum phosphate binders. 3. Non aluminic osteomalacia will be treated according to the same guidelines given for the uremic patients before dialysis. 4. Non aluminic adynamic bone disease will be cured by means aiming at stimulating PTH secretion as discontinuing 1 alpha hydroxylated vitamin D derivatives, and, if there is no hyperphosphatemia by discontinuation of calcium supplement. In case of hyperphosphatemia in dialysis patients CaCO3 doses have to be nevertheless increased after the dialysate calcium concentration (DCa) has been decreased in order to induce a negative perdialytic calcium balance for PTH secretion stimulation. In the near future substitution of CaCO3 by non calcemic non aluminic phosphate binders will suffice. 5. Osteitis fibrosa due to hyperparathyroidism will be treated first by securing an optimal vitamin D repletion (bringing plasma 25OH vitamin D around 30 and 60 ng/ml or 75-150 nmol/l) and by correcting hypocalcemia and hyperphosphatemia by CaCO3 at high doses (3-12 g/day) taken with the meals. In case of hypercalcemia dialysate calcium concentration will be decreased to correct it or, in a near future, CaCO3 will be decreased to 3 g/day and hyperphosphatemia will be controlled by non calcemic, non aluminic phosphate binders. When hyperphosphatemia is controlled whereas plasma calcium is normal or low, 1 alpha hydroxylated vitamin D derivatives can be administered. 6. Instrumental parathyroidectomy should be considered when plasma levels of intact PTH remain above 7 folds the upper limit of normal whereas hyperphosphatemia persists and hypercalcemia occurs in order to prevent thining of the corticals and subsequent fracture risk. In case of previous exposition to aluminum, a deferoxamine test and/or a bone biopsy will be performed to decide a long term DFO treatment before the parathyroidectomy in order to prevent the transformation of a mixed osteopathy into an aluminic adynamic bone disease. 7. The difficulty of hyperparathyroidism control in dialysis patients is due to poor compliance to phosphate binders and to irreversible parathyroid hyperplasia with occured before the dialysis stage. This stress the primary importance if its early prevention without iatrogenia by first CaCO3 and vitamin D repletion, as soon as the creatinine clearance decreases below 60 ml/min/1.73 m2." @default.
• W88459169 created "2016-06-24" @default.
• W88459169 creator A5015451578 @default.
• W88459169 creator A5030761574 @default.
• W88459169 creator A5032194918 @default.
• W88459169 creator A5039851586 @default.
• W88459169 creator A5044340801 @default.
• W88459169 creator A5048454909 @default.
• W88459169 creator A5051847656 @default.
• W88459169 creator A5057237962 @default.
• W88459169 creator A5057695803 @default.
• W88459169 date "2000-01-01" @default.
• W88459169 modified "2023-09-25" @default.
• W88459169 title "[Renal osteodystrophy (3); its treatment in dialysis patients]." @default.
• W88459169 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11213385" @default.
• W88459169 hasPublicationYear "2000" @default.
• W88459169 type Work @default.
• W88459169 sameAs 88459169 @default.
• W88459169 citedByCount "2" @default.
• W88459169 countsByYear W884591692012 @default.
• W88459169 crossrefType "journal-article" @default.
• W88459169 hasAuthorship W88459169A5015451578 @default.
• W88459169 hasAuthorship W88459169A5030761574 @default.
• W88459169 hasAuthorship W88459169A5032194918 @default.
• W88459169 hasAuthorship W88459169A5039851586 @default.
• W88459169 hasAuthorship W88459169A5044340801 @default.
• W88459169 hasAuthorship W88459169A5048454909 @default.
• W88459169 hasAuthorship W88459169A5051847656 @default.
• W88459169 hasAuthorship W88459169A5057237962 @default.
• W88459169 hasAuthorship W88459169A5057695803 @default.
• W88459169 hasConcept C124490489 @default.
• W88459169 hasConcept C126322002 @default.
• W88459169 hasConcept C141071460 @default.
• W88459169 hasConcept C2775945674 @default.
• W88459169 hasConcept C2776036575 @default.
• W88459169 hasConcept C2776169692 @default.
• W88459169 hasConcept C2776541429 @default.
• W88459169 hasConcept C2776699218 @default.
• W88459169 hasConcept C2778049618 @default.
• W88459169 hasConcept C2778063415 @default.
• W88459169 hasConcept C2778653478 @default.
• W88459169 hasConcept C2778838027 @default.
• W88459169 hasConcept C2779978075 @default.
• W88459169 hasConcept C2780551157 @default.
• W88459169 hasConcept C2781000923 @default.
• W88459169 hasConcept C2781208988 @default.
• W88459169 hasConcept C2781343496 @default.
• W88459169 hasConcept C519063684 @default.
• W88459169 hasConcept C71924100 @default.
• W88459169 hasConcept C90924648 @default.
• W88459169 hasConceptScore W88459169C124490489 @default.
• W88459169 hasConceptScore W88459169C126322002 @default.
• W88459169 hasConceptScore W88459169C141071460 @default.
• W88459169 hasConceptScore W88459169C2775945674 @default.
• W88459169 hasConceptScore W88459169C2776036575 @default.
• W88459169 hasConceptScore W88459169C2776169692 @default.
• W88459169 hasConceptScore W88459169C2776541429 @default.
• W88459169 hasConceptScore W88459169C2776699218 @default.
• W88459169 hasConceptScore W88459169C2778049618 @default.
• W88459169 hasConceptScore W88459169C2778063415 @default.
• W88459169 hasConceptScore W88459169C2778653478 @default.
• W88459169 hasConceptScore W88459169C2778838027 @default.
• W88459169 hasConceptScore W88459169C2779978075 @default.
• W88459169 hasConceptScore W88459169C2780551157 @default.
• W88459169 hasConceptScore W88459169C2781000923 @default.
• W88459169 hasConceptScore W88459169C2781208988 @default.
• W88459169 hasConceptScore W88459169C2781343496 @default.
• W88459169 hasConceptScore W88459169C519063684 @default.
• W88459169 hasConceptScore W88459169C71924100 @default.
• W88459169 hasConceptScore W88459169C90924648 @default.
• W88459169 hasIssue "8" @default.
• W88459169 hasLocation W884591691 @default.
• W88459169 hasOpenAccess W88459169 @default.
• W88459169 hasPrimaryLocation W884591691 @default.
• W88459169 hasRelatedWork W1596870183 @default.
• W88459169 hasRelatedWork W1982946692 @default.
• W88459169 hasRelatedWork W2131074353 @default.
• W88459169 hasRelatedWork W2155778995 @default.
• W88459169 hasRelatedWork W2327104397 @default.
• W88459169 hasRelatedWork W2333340595 @default.
• W88459169 hasRelatedWork W2431041547 @default.
• W88459169 hasRelatedWork W4207076267 @default.
• W88459169 hasRelatedWork W4290276508 @default.
• W88459169 hasRelatedWork W88459169 @default.
• W88459169 hasVolume "21" @default.
• W88459169 isParatext "false" @default.
• W88459169 isRetracted "false" @default.
• W88459169 magId "88459169" @default.
• W88459169 workType "article" @default.